NecstGen, a cell and gene therapy development and manufacturing facility, received a manufacturer’s license in early December (2022) for the GMP production of advanced cell and gene therapies (ATMPs). GMP is a quality assurance system that describes the minimum standard that a drug manufacturer must meet in the production process. “This is a highlight, a stamp of approval, on the work of our dedicated team,” says Paul Bilars, CEO of NecstGen.
Read our previous story about NecstGen here.